[Skip to Navigation]
Views 637
Citations 0
Invited Commentary
November 2017

Adopting the Results of Everest II Into Practice: A Clearer View From a Higher Level Study

Author Affiliations
  • 1Charlotte Eye, Ear, Nose, and Throat Associates, Charlotte, North Carolina
JAMA Ophthalmol. 2017;135(11):1214-1215. doi:10.1001/jamaophthalmol.2017.3118

Polypoidal choroidal vasculopathy (PCV), an oddity shown at fluorescein conferences 35 years ago, is now recognized as a common cause of neovascular maculopathy among those older than 50 years.1 Its prevalence has not increased, but new imaging techniques have revealed its features and ophthalmic consciousness has been raised. Randomized clinical trials that compare treatments, rather than case series, are now feasible.